BTIG lowered the firm’s price target on Staar Surgical (STAA) to $49 from $53 and keeps a Buy rating on the shares. The company’s Q3 results topped estimates, but the bulk of the focus remains on China, which deteriorated through the quarter, and Staar trimmed China’s growth outlook from 10% to 2% for FY24, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STAA: